SPTX News
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Seaport Therapeutics, Inc. (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company developing novel neuropsychiatric medicines, today announced the presentation of Phase 1 clinical data for GlyphAgo (SPT-320 or Glyph Agomelatine) at the 39th European College of...
Business Wire
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Seaport Therapeutics, Inc. (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company developing novel neuropsychiatric medicines, today announced the presentation of Phase 1 clinical data for GlyphAgo (SPT-320 or Glyph Agomelatine) at the 39th European College of...
Business Wire
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Seaport Therapeutics, Inc. (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that the first patient has been dosed in a Phase 2a clinical trial in Australia evaluating GlyphAgoTM (SPT-320...
Business Wire
Seaport Therapeutics to Participate in September Investor Conferences
Seaport Therapeutics, Inc. (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences...
Business Wire
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced positive topline results from the Phase 1 Driving...
Business Wire
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo (SPT-300 or Glyph...
Business Wire
Seaport Therapeutics to Present at Citis 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
Seaport Therapeutics, Inc. (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the following upcoming investor conferences: 21st...
Business Wire
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced financial results for the second quarter of 2026 and highlighted recent corporate and clinical progress. The...
Business Wire
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD...
Business Wire
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced financial results for the first quarter of 2026 and highlighted recent corporate and clinical progress. The...
Business Wire
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial...
Business Wire